Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca is making a small bet on tumor-bursting oncolytic viruses. The drug company is paying the French biotech firm Transgene $10 million to make five engineered vaccinia viruses that are designed to infect cancer cells and spur the body’s immune system to attack tumors. AstraZeneca suggests it will test the ability of these viruses to boost the efficacy of its existing checkpoint inhibitor therapies. Transgene may earn $3 million more in preclinical milestones and an undisclosed license fee for any viruses AstraZeneca chooses to develop.
This article has been sent to the following recipient: